Hudson Bay Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Hudson Bay Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,000	Closed	-$473K	–	1458
2025 Q4	$473K	Buy	+30,000	New	+$381K	﹤0.01%	875
2021 Q4	–	Sell	-25,000	Closed	-$1.42M	–	1119
2021 Q3	$1.42M	Sell	25,000 -50,000	-67%	-$2.47M	0.02%	694
2021 Q2	$3.3M	Buy	75,000 +20,000	+36%	+$979K	0.04%	476
2021 Q1	$2.71M	Sell	55,000 -9,600	-15%	-$479K	0.03%	473
2020 Q4	$2.72M	Buy	64,600 +19,600	+44%	+$862K	0.03%	324
2020 Q3	$2.06M	Buy	45,000 +40,254	+848%	+$1.95M	0.03%	350
2020 Q2	$238K	Buy	+4,746	New	+$246K	﹤0.01%	429

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Hudson Bay Capital Management's ENTA Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 30,000 shares — an estimated $473K sold.

Hudson Bay Capital Management first reported a position in ENTA in Q2 2020 and held it in 7 quarters. The position peaked at $3.3M in Q2 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Hudson Bay Capital Management reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Hudson Bay Capital Management sold 30,000 Enanta Pharmaceuticals shares in Q1 2026, an estimated $473K.
Hudson Bay Capital Management first reported a position in Enanta Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Hudson Bay Capital Management's Enanta Pharmaceuticals position peaked at $3.3M in Q2 2021.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.